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Early high plasma ST2, the decoy IL-33 receptor, in
children undergoing hematopoietic cell 
transplantation is associated with the development
of post-transplant diabetes mellitus
Post-transplant diabetes mellitus (PTDM) occurs in
60% of adults post-allogeneic hematopoietic cell trans-
plant (post-HCT) and has a negative impact on survival.1
Soluble Stimulation-2 (sST2), the decoy IL-33 receptor, is
the most validated predictor of refractory acute 
graft-versus-host disease (aGvHD) and death post-HCT.2
In adults, day +14 plasma sST2 concentration was elevat-
ed in those who develop PTDM.3 There are no studies
evaluating the incidence of PTDM and its relationship to
sST2 in pediatric hematopoietic cell transplant (HCT)
recipients. Here, we describe the incidence of PTDM in
children. We also relate its diagnosis to complications
post-HCT (aGvHD, veno-occlusive disease, and pediatric
intensive care unit [PICU] admission), and day +100 post-
HCT and overall survival. Furthermore, we correlated
day +14 plasma sST2 with the development of PTDM.  
Institutional review board approval was obtained prior
to the start of this study. Fifty-five HCT recipients, age ≤
21 years, were prospectively accrued and plasma samples
were collected at day +14 post-HCT. PTDM was defined
as no pre-existing diabetes, a first fasting blood sugar
≥126 mg/dL or random blood sugar ≥200 mg/dL during
the first 100 days post-HCT.1 Cumulative incidence func-
tion used the cohort median (23 ng/mL) of day +14 sST2
as a cut-off for risk categorization into high (above) and
low (below).  Unadjusted and adjusted hazard ratios (HR)
using Akaike’s Information Criterion (AIC) for multivari-
able selection were calculated. Time-dependent receiver
operating characteristic (ROC) curves for day +14 sST2
were generated to evaluate the area under the curve
(AUC) for risk of developing PTDM by days +30 and
+100 post-HCT. Death was used as a competing risk.
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Table 1. Demographics and patient characteristics stratified by the development of post-transplant diabetes mellitus.
                                                                                             PTDM                                      No PTDM                                         P
                                                                                             (n=17)                                       (n=38)                                            
Demographics
Sex (female)                                                                                          5 (29)                                                13 (34)                                                0.7260
Age (years)                                                                                      7.7 (0.8, 16.0)                                   10.0 (4.9, 13.8)                                         0.3769
Diagnoses
Lymphoid malignancy                                                                         7 (41)                                                 9 (24)
Myeloid malignancy                                                                            3 (18)                                                14 (38)                                                0.2315
Nonmalignant                                                                                       7 (41)                                                15 (39)                                                     
Disease Risk Index score                                                              3.0 (2.0, 5.0)                                      3.0 (3.0, 5.0)                                           0.3930
Conditioning regimen
Full                                                                                                             15                                                        25
Reduced                                                                                                     2                                                         10                                                    0.2830
Nonmyeloablative                                                                                    0                                                           3                                                           
Total body irradiation                                                                           6 (35)                                                15 (39)                                                0.7642
Donor source
Bone marrow                                                                                       6 (35)                                                26 (68)
Cord blood                                                                                           10 (59)                                                9 (24)                                                 0.0363
Peripheral blood                                                                                  1 (6)                                                   3 (8)                                                        
Donor status
Matched related                                                                                 3 (18)                                                18 (47)
Matched unrelated                                                                             7 (41)                                                12 (32)                                                0.3219
Mismatched unrelated                                                                      7 (41)                                                 8 (21)                                                       
2nd transplant                                                                                          3 (18)                                                  0 (0)                                                  0.0259
Body mass index at transplant                                                  19.1 (16.4, 21.6)                                17.7 (15.8, 22.4)                                        0.8275
Time to PTDM (median, range)                                                 19.0 (3.0, 44.0)                                             na                                                        na
Time to acute GvHD (median, range)                                     60.0 (32.0, 70.0)                                14.0 (14.0, 14.0)                                          na*
High dose corticosteroids use 
prior to the development of                                                              4 (24)                                                 5 (13)                                                 0.4348
PTDM or any time during the 
first 100 days post HCT                                                                              
Time to corticosteroids (median, range)                                9.5 (0.0, 19.0)                                     2 (0.0, 21.0)                                            0.9999
Values displayed are frequencies with (%) for categorical variables and were compared using c2 or Fisher’s Exact test where appropriate.  % are rounded to the nearest
whole number.  Continuous variables are displayed in medians (interquartile ranges) and were compared with Wilcoxon rank sum test. *P-value not obtained due to only
one data point for time to aGvHD for the no PTDM group.  PTMD: post-transplant diabetes mellitus; aGvHD: acute graft-versus-host disease; na: not analysed. 
PTDM was diagnosed in 31% of children.  The median
day to development of PTDM was day +19 post-HCT
(range: 3.0, 44.0 days). Demographics including sex, age,
malignant diagnosis, matched or related donor status, dis-
ease risk index, high-dose corticosteroids ( ≥1 mg/kg
methylprednisolone equivalent for at least 72 hours), and
body mass index did not differ significantly (Table 1).
Those who received a cord blood transplant were more
likely to develop PTDM (P=0.0363). All patients (n=3)
who underwent a second transplant developed PTDM
(P=0.0259). Outcomes were worse in those who devel-
oped PTDM (Table 2).  Univariate analysis showed those
with PTDM had increased rates of aGvHD (P=0.0085).
Four patients diagnosed with PTDM also had aGvHD
grade I-IV with a median time to development of 60 days
(range: 32-70 days) (Table 1). Only three of these patients
had a maximum grade II-IV aGvHD.  Two of these three
patients were diagnosed with aGvHD prior to the PTDM
diagnosis (two and three days prior respectively). One
patient was diagnosed with aGvHD 36 days after the diag-
nosis of PTDM. There was no difference in the use of high
dose steroids and the median time to steroid use was not
statistically different (Table 1). Those with PTDM were
also more likely to be admitted to the intensive care unit
(71% vs. 8%, P<0.0001) and more likely to receive
mechanical ventilation (53% vs. 5%, P=0.001).  Finally,
those with PTDM also had decreased survival at 100 days
(P=0.0070) as compared to patients who did not develop
PTDM. While not reaching statistical significance, more
patients with PTDM died of non-relapsed mortality
(NRM) than those who did not develop PTDM (P=0.14).
Those who developed PTDM had a higher mean sST2
level at day +14 post HCT: 95.1±90.0 compared to those
who did not develop PTDM: 28.2±28.7, P=0.0002.  Also,
examining sST2 as a continuous variable, we found a
higher risk for PTDM (hazard ratio [HR]=1.013, 95%
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Figure 1. sST2 measured on day +14 post-allogeneic hematopoietic cell transplant is associated with the development of post-transplant diabetes mellitus
and survival. (A) Cumulative incidence function graphs for risk based on sST2 level at day +14 post-allogeneic hematopoietic cell transplant (post-HCT).
Cumulative incidence of the development of post-transplant diabetes mellitus (PTDM) comparing those at high risk (sST2 > cohort median of 23 ng/mL) to those
at low risk (sST2 < cohort median of 23 ng/mL). Death was used as a competing risk. (B) Time dependent receiver operating characteristic curve for sST2 meas-
ured at day +14 post-HCT. Time dependent receiver operating characteristic curves using sST2 levels measured on day +14 post-HCT to determine the risk of
developing PTDM by day 30 and 100 post-HCT. Death was used as a competing risk. (C) Survival curve by PTDM status. Survival stratified by the development
of PTDM.  Those in who developed PTDM (n=17), illustrated in red, had worse 1-year survival that those who did not developed PTDM (n=38), illustrated in blue.
Log-rank P-value=0.0035. (D) Survival curve by high and low sST2 . Survival stratified by high sST2 (above the cohort median of 23 ng/mL) and low sST2 (below
23 ng/mL).  Those with a high sST2 on day +14 had a worse probability of survival at 1 year than those who had a low sST2. Log-rank P-value=0.0072.
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confidence interval [CI]: 1.01-1.02, P<0.0001). We then,
in an effort to identify a clinically useful cutpoint, catego-
rized patients into high and low risk, using the median
sST2 level as a cutpoint.  Illustrated with cumulative inci-
dence function graphs (Figure 1A), those with high sST2
on day +14 had a higher risk of developing PTDM 
(HR=3.92, 95% CI: 1.42-10.84, unadjusted P=0.0085).
Using death as a competing risk and adjusting for donor
source and second transplant, high sST2 was still strong-
ly associated with PTDM occurrence within 100 days
post-HCT (HR=4.06, 95% CI: 1.55-10.62, adjusted
P=0.0043). A time-dependent ROC curve, with a com-
peting risk of death, demonstrated that sST2 had an
excellent ability to discriminate the development of
PTDM by 30 (AUC=0.86) and 100 days (AUC=0.80)
post-HCT (Figure 1B). Survival curves, estimated by
Kaplan-Meier curves method, showed that patients with
PTDM had significantly lower survival than those who
did not, log-rank P-value for the difference of 0.0035
(Figure 1C). Those with a high sST2 also had a lower sur-
vival, similar to the survival curve by PTDM status, log-
rank P-value of 0.0072 (Figure 1D). To examine if sST2
was different even earlier in the transplant course, we
investigated samples at day -7 (pre-HCT) on 10 no
PTDM versus 18 PTDM patients. In this small sample
size, the mean +/- standard error of the mean (SEM) was
23.3±6.7 for those with PTDM compared to 30.3±13.7 in
those who did not develop PTDM, the P-value=0.7184
was not statistically significantly different. 
This is one of the first studies reporting the incidence
of PTDM in children post-HCT, which unexpectedly
appears common. Furthermore, to our knowledge, this is
the first manuscript to report an association between
sST2 and PTDM in a pediatric cohort. In adults with
hyperglycemia post-HCT, studies have found increased
risk for aGvHD and nonrelapsed mortality.4,5 Our study
found similar results in a pediatric population. Children
with PTDM have increased aGvHD and the need for crit-
ical care, and subsequently decreased overall survival.
Surprisingly, but similar to a recent adult study,6 there
was not an association of the use of high dose corticos-
teroids with PTDM. This suggests that HCT acutely
modifies glucose homeostasis in recipients too young to
have changes induced by age and other common factors.
Perhaps, as suggested in non-transplant diabetes, PTDM
is induced by inflammation resulting in insulin
resistance.7 Supporting this is our finding that children
with high plasma sST2, as early as 14 days post-HCT,
had a significantly higher risk to develop PTDM. This is
similar to adults with type-2 diabetes and PTDM.1,8
Importantly, in our cohort, similar to the adult cohort, the
best statistical model did include high day +14 sST2 but
not aGvHD.3 These data suggest that the ST2/IL-33 path-
way plays a role in maintaining the metabolic equilibri-
um after HCT. Fasting pre-HCT glucose levels have been
shown to identify PTDM susceptibility in adults6 and
testing for it pre-HCT is crucial. However, fasting glucose
levels are sometimes difficult to perform in children
younger than 10 years and we believe that early testing
of sST2 levels may help identify those at higher risk for
PTDM development and help guide the frequency of
blood glucose monitoring, particularly in this younger
population. As our adult patients, we recommend testing
for pre-HCT fasting glucose levels in children. In addi-
tion, early testing of sST2 levels may help identify those
at higher risk for PTDM development in children difficult
to evaluate by pre-HCT fasting glucose levels with the
goal of early prevention and treatment of peripheral
insulin resistance, which may improve survival.
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Table 2. Outcomes and multivariate analyses of sST2 levels based on post-transplant diabetes mellitus status.
                                                                          PTDM                                              No PTDM                                                  P
                                                                          (n=17)                                               (n=38)                                                      
HCT Outcomes, n (%)
aGvHD grade I-IV                                                         5 (29)                                                            1 (3)                                                              0.0085
Veno-occlusive disease                                              5 (29)                                                            3 (8)                                                              0.0908
Survival Outcomes, n (%)
Survival 100 days post-HCT                                       13 (77)                                                        38 (100)                                                          0.0070
Survival 1 year post-HCT                                           10 (59)                                                         34 (90)                                                           0.0239
Overall survival                                                             9 (53)                                                          32 (84)                                                           0.0208
Causes of Death
Relapsed Mortality                                                      3 (38)                                                           5 (83)                                                               0.14
Nonrelapsed Mortality*                                             5 (63)                                                           1 (17)
Day +14 sST2 Biomarker > 23 ng/mL
Unadjusted HR (95% CI)                                  3.92 (1.42-10.84)                                              reference                                                         0.0085
Adjusted HR (95% CI)                                       4.06 (1.55-10.62)                                              reference                                                         0.0043
Values displayed are frequencies with (%) for categorical variables and were compared using Chi Squared or Fisher’s Exact test where appropriate.  % are rounded to the
nearest whole number.  HR: hazard ratio and CI: confidence interval were adjusted based on Akaike’s Information Criterion (AIC) for second transplant and donor
source.*Causes of non-relapsed mortality (NRM) included infection (n=1), acute graft-versus-host disease (aGVHD) (n=2), and SOS (n=2) in the PTDM group and pul-
monary hemorrhage in the group with no PTDM. HCT:  hematopoietic cell transplant; n: number.
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